Summary
The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue inside of your bones. Lomecel-B uses MSCs from bone marrow of unrelated young healthy donors. These are called "allogeneic", and do not require donor matching to the patient.
Conditions
Hypoplastic Left Heart Syndrome
Recruitment Status
Recruiting
Eligibility Criteria
Inclusion:
All participants must have HLHS (includes all types) requiring Stage II palliation (Glenn or Hemi-Fontan operation).
Exclusion:
Requirement for ongoing mechanical circulatory support immediately prior to Stage II palliation within 5 days
Need for concomitant surgery for aortic coarctation or tricuspid valve repair or Endocardial fibroelastosis (EFE) resection or left ventricle recruitment procedures
Undergoing the Stage I (Norwood) procedure that does not have HLHS
Serum positivity for: human immunodeficiency virus (HIV); hepatitis B virus surface antigen (HBV BsAg); and/or viremic hepatitis C virus (HCV). This criterion can be ascertained by one of three ways:
Documented history of mother's testing conducted during pregnancy
Documented history of participants testing.
If above documentation is not available blood will be obtained from participant at Screening/Baseline.
Parent/guardian that is unwilling or unable to comply with necessary follow-up
Unsuitability for the study based on the Investigator's clinical opinion
Known hypersensitivity to dimethyl sulfoxide (DMSO)
Presence of a pacemaker, or anticipated placement of a pacemaker, at the time of the Stage II palliation
Intervention
Intervention Type
Intervention Name
Biological
Lomecel-B medicinal signaling cells
Phase
Phase 2
Gender
All
Min Age
N/A
Max Age
12 Months
Download Date
April 9, 2024
Principal Investigator
This field has been modified from ClinicalTrials.gov to show a contact specific to Boston Children's.
Primary Contact Information
Breanna.Piekarski@cardio.chboston.org
617-919-4457
This field has been modified from ClinicalTrials.gov to show a contact specific to Boston Children's.
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team: